Lumacaftor, also known as VX-809, is a potent CFTR corrector, many be useful for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation. Cystic fibrosis (CF) is a genetic disorder that causes multiorgan morbidity and premature death, most commonly from pulmonary dysfunction.
Hadida Ruah, Sara; Hamilton, Matthew; Miller, Mark; Grootenhuis, Peter D. J.; Bear, Brian; Mccarthy, Jason; Zhou, Jinglan. Preparation of N-pyridinyl carboxamide derivatives as modulators of ATP-binding cassette transporters. WO 2007056341. (Assignee Vertex Pharmaceuticals Incorporated, USA)
Hadida-Ruah, Sara; Hamilton, Matthew; Miller, Mark; Grootenhuis, Peter D.J.; Bear, Brian; McCartney, Jason; Zhou, Jinglan; Van Goor, Frederick. Preparation of N-pyridinyl carboxamide derivatives as modulators of ATP-binding cassette transporters. US 20080019915. (Assignee Vertex Pharmaceuticals Inc., USA)
Young, Christopher. Dosage units of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid. WO 2010037066. (Assignee Vertex Pharmaceuticals Inc., USA)
Keshavarz-Shokri, Ali; Zhang, Beili; Krawiec, Mariusz. Preparation of Lumacaftor for therapeutical use. WO 2011127290. (Assignee Vertex Pharmaceuticals Incorporated, USA)
Van Goor, Fredrick F.; Alargova, Rossitza Gueorguieva; Alcacio, Tim Edward; Arekar, Sneha G.; Binch, Hayley Marie; Botfield, Martyn Curtis; Fanning, Lev Tyler Dewey; Grootenhuis, Peter Diederik Jan; Hurley, Dennis James; Johnston, Steven C.; Kadiyala, Irina Nikolaevna; Kaushik, Ritu Rohit; Keshavarz-Shokri, Ali; Krawiec, Mariusz; Lee, Elaine Chungmin; Luisi, Brian; Medek, Ales; Mudunuri, Praveen; Numa, Mehdi; Sheth, Urvi Jagdishbhai; Silina, Alina; Sullivan, Mark Jeffrey; Verwijs, Marinus Jacobus; Yang, Xiaoqing; Young, Christopher Ryan; Zaman, Noreen Tasneem; Zhang, Beili; Zhang, Yuegang; Zlokarnik, Gregor. Pharmaceutical compositions for treatment of CFTR-mediated diseases. WO 2011133953. (Assignee Vertex Pharmaceuticals Incorporated, USA)
Siesel, David Andrew. Process for the preparation of cycloalkylcarboxamido-pyridine benzoic acids. US 8461342. (Assignee Vertex Pharmaceuticals Incorporated, USA)
Verwijs, Marinus Jacobus; Karkare, Radhika; Moore, Michael Douglas. Preparation of 3-(pyridin-2-yl)benzoic acid and 4-oxo-1H-quinoline-3-carboxamide derivative and pharmaceutical compositions for the treatment of CFTR mediated diseases. WO 2014071122. (Assignee Vertex Pharmaceuticals Incorporated, USA)
Abela, Alexander Russell; Alcacio, Timothy; Anderson, Corey; Angell, Paul Timothy; Baek, Minson; Clemens, Jeremy J.; Cleveland, Thomas; Ferris, Lori Ann; Grootenhuis, Peter Diederik Jan; Gross, Raymond Stanley; Gulevich, Anton; Hadida Ruah, Sara Sabina; Hsia, Clara Kuang-Ju; Hughes, Robert M.; Joshi, Pramod Virupax; Kang, Ping; Keshavarz-Shokri, Ali; Khatuya, Haripada; Krenitsky, Paul John; Mccartney, Jason; Miller, Mark Thomas; Paraselli, Prasuna; Pierre, Fabrice Jean Denis; Shi, Yi; Shrestha, Muna; Siesel, David Andrew; Stavropoulos, Kathy; Termin, Andreas P.; Uy, Johnny; Van Goor, Fredrick F.; Young, Tomothy John; Zhou, Jinglan. Preparation of N-heteroaroylsulfonamide derivatives as cystic fibrosis transmembrane conductance regulator modulators for treatment of cystic fibrosis. WO 2018107100. (Assignee Vertex Pharmaceuticals Incorporated, USA)
Bollu, Ravindra Babu; Dalasingh, Prasanta Kumar; Dwarampudi, Sushmita; Annem, Chandrahasa Reddy; Vasireddi, Uma Maheswer Rao. Process for the preparation of lumacaftor and its crystalline forms. WO 2018127846. (Assignee Laurus Labs Limited, India)
Haseltine, Eric L.; Moskowitz, Samuel; Robertson, Sarah; Waltz, David. Methods of treatment for cystic fibrosis WO 2019018395. (Assignee Vertex Pharmaceuticals Incorporated, USA)
